替罗非班在急诊PCI患者中应用的疗效和安全性观察

Value and safety of Tirofiban in patients with primary percutaneous coronary intervention

目的观察国产替罗非班在ST段抬高型急性心肌梗死(STEMI)患者急诊介入治疗中应用的疗效和安全性。方法符合急性心肌梗死入选标准的患者83例,按时间顺序分为未应用替罗非班组(对照组37例)及急诊室应用替罗非班组(替罗非班组46例)。观察两组患者心电图变化以及出血并发症。结果与对照组相比,替罗非班组术后30分钟ST段回落明显增加(87.0%vs64.9%,P<0.05),出血并发症比对照组有增多趋势,但无统计学差异(6.5%vs0%,P>0.05)。结论替罗非班应用于急诊介入治疗急性心肌梗死是安全有效的。

Objective To observe the value and safety of platelet GP Ⅱb/Ⅲ a antagonist Tirofiban during primary percutaneous coronary intervention （PCI） in patients with acute ST-segment elevation myocardial infarction （STEMI）.Methods 83 patients with acute myocardial infarction were divided into two groups.37 patients in control group who were not treated with Tirofiban, while 46 patients in experimental group were treated with Tirofiban.The changes of ECG and bleeding rate were evaluated.Results In contrast with control group,the patients of Tirofiban group had a significant improvement of ECG （87.0% vs 64.9% ,P〈0.05）and bleeding occurred in 6.5% of the Tirofiban group and in 0% of control group.Conclusion .Tirofiban is effective and safe in patients with acute ST-segment elevation myocardial infarction （STEMI） during primary PCI.